-transparent.png){kind=logo}
Cultured P388/S mouse lymphoma cells resistant to 5-bromodeoxyuridine (BUdR) and deficient in thymidine kinase (TK-) were fused with P388/DAG cells resistant to 1,2:5,6-dianhydrogalactitol (DAG), an anticancer alkylating agent, and to 6-thioguanine (6-TG) and deficient in hypoxanthine phosphoribosyl-transferase (HPRT-). Sensitivity to DAG in the hybrid line was very close to that in the P388/DAG line, which means that resistance to DAG was inherited in a quasi-dominant manner. Hybrid cells showed cross-resistance, similar to that of the DAG-resistant line, to two other hexitols, dibromodulcitol (DBD) and disuccinyldianhydrogalactitol (DisuDAG).
Related Publications
I Pályi, and
J Bence, and
K Szikla, and
L Hullán
May 1978,
Cancer treatment reports,
I Pályi, and
J Bence, and
K Szikla, and
L Hullán
October 1976,
Clinical chemistry,
I Pályi, and
J Bence, and
K Szikla, and
L Hullán
February 1987,
Yao xue xue bao = Acta pharmaceutica Sinica,
I Pályi, and
J Bence, and
K Szikla, and
L Hullán
October 1972,
Cancer chemotherapy reports,
I Pályi, and
J Bence, and
K Szikla, and
L Hullán
March 1980,
The Biochemical journal,
I Pályi, and
J Bence, and
K Szikla, and
L Hullán
January 1981,
Carcinogenesis,
I Pályi, and
J Bence, and
K Szikla, and
L Hullán
September 1983,
Yao xue xue bao = Acta pharmaceutica Sinica,
I Pályi, and
J Bence, and
K Szikla, and
L Hullán
October 1979,
International journal of radiation biology and related studies in physics, chemistry, and medicine,
I Pályi, and
J Bence, and
K Szikla, and
L Hullán
December 1980,
Zhongguo yao li xue bao = Acta pharmacologica Sinica,
I Pályi, and
J Bence, and
K Szikla, and
L Hullán
March 1977,
Journal of the National Cancer Institute,
